Inflation Trends - In October 2025, the CPI increased by 0.2% year-on-year, while the core CPI rose by 1.2%, marking a significant increase from the previous values of -0.3% and 1% respectively[6] - The tourism CPI in October was notably high at 2.1%, influenced by the Mid-Autumn Festival, compared to 0.9% in the previous month[6] - Food prices showed a year-on-year decrease of -2.9% in October, an improvement from -4.4% in September, indicating a recovery in consumer demand[6] Policy Impact - Government consumption policies have shown a substantial leverage effect, with industrial consumer goods prices excluding energy rising by 2.0%, up from 1.8% in the previous month[6] - The PPI decreased at a slower rate of -2.1% year-on-year in October, an improvement from -2.3% in September, reflecting effective supply-side policies[6] - The prices in traditional high-energy-consuming industries improved, with the PPI for the mining and raw materials sectors increasing by 1.2 and 0.4 percentage points respectively[6] Future Outlook - Despite expected inflation declines post-holiday, the effects of various policies are anticipated to continue supporting economic growth, shifting the focus from external to high-quality domestic demand[6] - The implementation of policy-driven financial tools by the end of October is expected to further enhance domestic demand, with tangible results reflected in upcoming data[6] - Risks remain, particularly from geopolitical conflicts that could lead to unexpected fluctuations in commodity prices[6]

宏观经济 | 动态跟踪 出口转跌非趋势，资本品出口潜力仍在 10 月进出口点评 研究结论 | 孙国翔 | 执业证书编号：S0860523080009 | | --- | --- | | | sunguoxiang@orientsec.com.cn | | | 021-63326320 | | 孙金霞 | 执业证书编号：S0860515070001 | | | sunjinxia@orientsec.com.cn | | | 021-63326320 | | 王仲尧 | 执业证书编号：S0860518050001 | | | 香港证监会牌照：BQJ932 | | --- | --- | | | wangzhongyao1@orientsec.com.cn | | | 021-63326320 | | 陈至奕 | 执业证书编号：S0860519090001 | | | 香港证监会牌照：BUK982 | | | chenzhiyi@orientsec.com.cn | | | 021-63326320 | | 降息交易减速，方向尚未改变：——2025 | 2025-11-02 | | --- | --- | | 年 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][7] Core Views - The company's revenue for the first three quarters of 2025 reached 231.88 billion yuan, a year-on-year increase of 14.85%, with net profit attributable to the parent company at 57.51 billion yuan, up 24.50% year-on-year [11] - The growth is driven by the continuous release of innovative drug research results and accelerated overseas licensing cooperation, contributing to incremental performance [11] - The company has strengthened its innovative pipeline, with significant product approvals and a robust pipeline in various therapeutic areas [11] Financial Performance Summary - Revenue (in million yuan): - 2023A: 22,820 - 2024A: 27,985 - 2025E: 34,184 - 2026E: 38,303 - 2027E: 43,925 - Year-on-year growth rates: 2024A: 22.6%, 2025E: 22.2%, 2026E: 12.0%, 2027E: 14.7% [6][13] - Net profit (in million yuan): - 2023A: 4,302 - 2024A: 6,337 - 2025E: 8,755 - 2026E: 10,043 - 2027E: 11,403 - Year-on-year growth rates: 2024A: 47.3%, 2025E: 38.2%, 2026E: 14.7%, 2027E: 13.5% [6][13] - Earnings per share (in yuan): - 2023A: 0.65 - 2024A: 0.95 - 2025E: 1.32 - 2026E: 1.51 - 2027E: 1.72 [6][13] Strategic Developments - The company has achieved significant overseas licensing agreements, with over 800 million USD in upfront payments in the first three quarters of 2025 [11] - Recent collaborations include agreements with GSK, Glenmark, and Braveheart Bio, indicating a strong push towards internationalization [11] - The company is focusing on expanding its innovative drug portfolio, with multiple new drug applications accepted by NMPA [11]

Group 1: Report Industry Investment Rating - No relevant content provided Group 2: Core Viewpoints of the Report - The pre - profit - taking behavior of convertible bonds has eased, but under the current high absolute price and high valuation, the volatility has intensified and the bond nature has weakened. November may be the last wave of adding positions from the perspective of institutional behavior. The current high - valuation situation is expected to remain unchanged [5][8]. - The view on the future of convertible bonds is neutral. It is difficult for convertible bond valuations to have a logic of continuous strengthening. It is likely to fluctuate around the current point. The key to the subsequent trend lies in equities. Investors should appropriately lower the return expectations of convertible bonds, cash out and switch in a timely manner, and low - position institutions can actively allocate on dips. The trading opportunities of convertible bonds are greater than the trend opportunities [5][8]. - Despite the overseas capital market turmoil, the domestic market has slightly recovered this week, hovering around 4000 points, indicating sufficient market confidence. Some over - valued sectors have corrected in the short term, and the weight sectors have temporarily attracted attention. The technology - led slow - bull market remains unchanged, and the subsequent equity trend is still bullish [5][8]. Group 3: Summary According to the Directory 1. Convertible Bond Views: Double - Low Performance Stands Out, Style Slightly Switches - The pre - profit - taking behavior of convertible bonds has eased, but with high absolute prices and valuations, volatility has increased and bond nature has weakened. November may be the last chance for institutional position - adding. The high - valuation situation is expected to remain. The view on convertible bonds is neutral, with the key to subsequent trends in equities. Investors should adjust expectations, cash out and switch, and low - position institutions can allocate on dips. The domestic market has recovered slightly, and the technology - led slow - bull market remains [8]. 2. Convertible Bond Review: Index Approaches Previous High, Valuation Slightly Rises 2.1 Market Overall Performance: Most Indexes Close Higher, Trading Volume Declines - This week, most equity indexes closed slightly higher. The Shanghai Composite Index led the gains with a 1.08% increase, while the North - Bound 50 Index fell 3.79%. In terms of industries, power equipment, coal, and petroleum and petrochemicals led the rise, while beauty care, computer, and pharmaceutical biology led the decline. The average daily trading volume decreased by 3108.43 billion yuan to 2.01 trillion yuan. The top - ten rising convertible bonds last week were Zhongneng, Zhenhua, etc., and some convertible bonds were more active in trading [11]. 2.2 Trading Volume Continues to Increase, Double - Low and Large - Cap High - Rating Convertible Bonds Perform Well - This week, convertible bonds performed well, following the rise of equities. The average daily trading volume slightly increased to 68.526 billion yuan. The CSI Convertible Bond Index rose 0.86%, the parity center rose 1.0% to 114.4 yuan, and the conversion premium rate center remained flat at 18.7%. In terms of style, double - low and large - cap high - rating convertible bonds performed well, while high - price and small convertible bonds performed weakly [14].

Investment Rating - The report maintains a "Positive" investment rating for the non-ferrous and steel industry in China [6]. Core Viewpoints - The report emphasizes the importance of addressing overseas electricity shortages with Chinese solutions, particularly in the context of rising industrial electricity costs due to increasing energy prices in major countries [9][14]. - It highlights the potential for significant growth in the electrolytic aluminum sector driven by export demand, as overseas power supply issues lead to production cuts [14]. - The report also points out investment opportunities in the special steel sector, particularly related to advancements in nuclear fusion technology [15]. - The lithium carbonate sector is expected to benefit from a surge in overseas energy storage demand, with prices across the supply chain showing signs of recovery [16]. Summary by Sections 1. Non-Ferrous Metals - The report suggests that electrolytic aluminum, special steel, and lithium carbonate are primarily driven by domestic demand, but it presents a contrasting view that focuses on overseas electricity shortages as a growth opportunity [9][13]. - The electrolytic aluminum sector is poised for a revaluation due to strong production cut expectations stemming from overseas electricity shortages [14]. - The special steel sector is highlighted for its potential growth linked to nuclear fusion advancements, with significant demand expected for materials that can withstand extreme conditions [15]. - The lithium carbonate sector is experiencing a price rebound, with recent contracts indicating a positive outlook for the entire supply chain [16]. 2. Steel Industry - The steel industry is facing short-term profitability pressures, with slight declines in iron and steel production noted [17][19]. - Inventory levels for both social and steel mill stocks are decreasing, indicating a tightening supply [24]. - The report notes a general decline in steel prices, with various product categories experiencing price drops [34]. - Cost pressures are evident, with mixed trends in raw material prices impacting profitability across different steel production processes [27][30]. 3. New Energy Metals - The report indicates a significant year-on-year increase in lithium carbonate production, reflecting a robust supply response to market demand [39]. - The demand for new energy vehicles remains strong, with production and sales figures showing substantial growth [43]. - Price trends for lithium and nickel are mixed, with lithium prices experiencing a notable decline while cobalt prices have seen increases [48][50].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 40.61 CNY based on a projected PE of 31 times for 2026 [3][6]. Core Insights - The company's robot business is set to ramp up, positioning itself as a leading platform in the domestic and international markets, with significant orders and expected deliveries of humanoid and quadruped robots [11]. - The company is expected to benefit from strong demand for consumer electronics, particularly from major North American clients, with anticipated double-digit growth in iPhone revenue [11]. - The company is leveraging its technological capabilities across various sectors, including consumer electronics and automotive electronics, establishing a competitive edge through vertical integration and horizontal expansion [11]. Financial Forecasts - The projected net profits for the company from 2025 to 2027 are 5 billion, 6.9 billion, and 8.9 billion CNY respectively, with slight adjustments made to previous forecasts [3][12]. - Revenue is expected to grow from 54.49 billion CNY in 2023 to 143.2 billion CNY in 2027, reflecting a compound annual growth rate of approximately 21.5% [5][13]. - The company's gross margin is projected to remain stable around 15% over the forecast period, with net profit margins gradually increasing from 5.5% in 2023 to 6.2% in 2027 [5][13].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 27.74 CNY, based on a revised average P/E ratio of 19x for comparable companies in 2026 [3][6]. Core Insights - The company is expected to optimize its self-developed game portfolio in 2026, leading to an increase in gross profit margin as new projects are launched. The forecasted net profit for the company from 2025 to 2027 is 3.072 billion, 3.234 billion, and 3.546 billion CNY respectively, reflecting adjustments based on game launch schedules and marketing data [3][10]. - The third quarter of 2025 saw a revenue of 3.98 billion CNY, a year-on-year decrease of 3%, primarily due to declines in older games. However, the net profit attributable to the parent company increased by 49% to 940 million CNY, attributed to controlled sales expenses [10]. Financial Summary - **Revenue Forecast**: The company’s revenue is projected to be 16.086 billion CNY in 2025, with a year-on-year decline of 7.8%, followed by a recovery to 16.873 billion CNY in 2026 and 17.366 billion CNY in 2027 [5][12]. - **Profitability Metrics**: The gross margin is expected to decline to 76.7% in 2025 but recover to 79.8% by 2027. The net profit margin is projected to increase from 19.1% in 2025 to 20.4% in 2027 [5][12]. - **Earnings Per Share (EPS)**: The EPS is forecasted to rise from 1.39 CNY in 2025 to 1.60 CNY in 2027 [5][12]. - **Valuation Ratios**: The company’s P/E ratio is expected to decrease from 16.5 in 2025 to 14.3 in 2027, indicating a potentially attractive valuation [5][12]. Product Development and Market Position - The company has a robust product pipeline with multiple global projects set to launch, including genres such as MMORPG, SLG, and card games. Key upcoming titles include "赘婿" and "代号 MLK" [10][12]. - The performance of existing games like "Puzzles & Survival" has stabilized, while new titles like "斗罗大陆：猎魂世界" are expected to contribute positively to revenue in the latter half of the year [10].

Investment Rating - The report maintains a "Positive" outlook for the industry, indicating a relative strength of over 5% compared to market benchmarks [8][12]. Core Insights - The People's Bank of China has increased its gold reserves for 12 consecutive months, with a total of 7.409 million ounces as of October, reflecting a significant increase in value to $297.209 billion, up by $13.918 billion from the previous month [8]. - The proportion of gold in China's foreign exchange reserves has risen to 8.89%, an increase of 0.5 percentage points from the previous month, indicating potential for further growth compared to other major countries [8]. - The ongoing trend of de-dollarization and the internationalization of the Renminbi is expected to drive gold prices upward, with projections suggesting a potential rise to $4,500 to $5,000 per ounce in the medium term [8]. Summary by Sections Industry Overview - The report highlights the tightening supply expectations in the non-ferrous and steel sectors, suggesting potential investment opportunities in these segments [7]. Market Dynamics - The recent public consultation on the new "Steel Industry Capacity Replacement Measures" indicates that supply-side reforms may be imminent, which could positively impact the market [7]. Investment Recommendations - The report recommends focusing on leading global copper and gold mining companies, particularly Zijin Mining (601899), which is expected to see significant growth in copper production in 2026 [8].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 28.08 CNY based on a PE valuation of 18X for comparable companies in 2026 [4][6]. Core Insights - The company has shown significant performance growth driven by the booming wind power sector, with a notable increase in high-end materials potentially enhancing profit margins [2][10]. - The company's net profit for the first three quarters of 2025 reached approximately 249 million CNY, reflecting a substantial year-on-year growth of 213.65% [10]. - The report highlights the expected continuation of profit growth due to the release of production capacity and cost reduction initiatives, particularly in the offshore wind power segment [10]. Financial Performance Summary - The company's projected revenue for 2025 is 5.468 billion CNY, representing a year-on-year growth of 36.6% [4][13]. - The net profit attributable to the parent company is forecasted to be 318 million CNY in 2025, with a remarkable growth rate of 177.2% compared to the previous year [4][13]. - The gross margin is expected to improve to 20.8% in 2025, with net profit margin reaching 5.8% [4][13]. - The company's earnings per share (EPS) is projected to be 1.13 CNY in 2025, increasing to 2.03 CNY by 2027 [4][13].

Investment Rating - The report maintains a "Buy" rating for the company [3][6]. Core Insights - The company has introduced a new ATTC platform that enhances innovation in drug development, particularly in cancer and immune disease treatments [10]. - The first candidate drug from the ATTC platform, HMPL-A251, shows promising anti-tumor activity and is expected to enter clinical development by the end of the year [10]. - The company's core pipeline is progressing steadily, with key data readouts for the drug Savolitinib anticipated soon, which could lead to market expansion [10]. Financial Forecasts and Investment Recommendations - Projected revenues for the company from 2025 to 2027 are $600.43 million, $705.84 million, and $796.91 million respectively, with a target price of HKD 33.29 for 2026 [3][5]. - The company is expected to see significant growth in net profit, with a forecasted increase of 1110.15% in 2026 [5]. - The report highlights a projected net profit margin of 76.12% in 2026, indicating strong profitability potential [5].